Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Ultra-Short Course of Subcutaneous Immunotherapy Well Tolerated in Patients With Seasonal Allergic Rhinoconjunctivitis: Presented at EAACI - (DGDispatch)
    Sublingual Immunotherapy Even More Effective During Pollen Peak Season in Children With Rhinoconjunctivitis: Presented at EAACI - (DGDispatch)
    Children and Adolescents With Grass-Pollen-Allergic Rhinoconjunctivitis Benefit Similarly From 5-Grass Sublingual Monotherapy: Presented at EAACI - (DGDispatch)
    Sublingual Monotherapy Improves Quality of Life in Polysensitised Patients With Allergic Rhinitis: Presented at EAACI - (DGDispatch)
    Recombinant Bet v 1 Sublingual Tablets in Birch Allergy Well Tolerated Up to 50 mcg: Presented at EAACI - (DGDispatch)

    News archive

     Recent webcasts/CME - Allergy Other
    • Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
    • Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
    • What Is the Best Approach to Treating Alpha1-Antitrypsin (AAT) Deficiency?
    • Improving Outcomes for Patients With Allergic Rhinitis: An Update From Philadelphia
    • Recognition and Management of Anaphylaxis

      Webcasts/CME archive

       Recent cases - Allergy Other
        Acute Allergic Reaction due to Milk Proteins Contaminating Lactose Added to Corticosteroid for Injection
        Acute Generalized Exanthematous Pustulosis (AGEP) Triggered by a Spider Bite
        Anaphylactic Reaction to Camomile Tea
        Acute Allergic Interstitial Nephritis After Use of Pantoprazole
        Allergic Enterocolitis and Protein-Losing Enteropathy as the Presentations of Manganese Leak From an Ingested Disk Battery: A Case Report

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Tacrolimus Ointment Helps Some Difficult Cases of Pediatric Eczema: Presented at WAC

        By Norra MacReady

        MUNICH, GERMANY -- July 4, 2005 -- Topical tacrolimus ointment may help some children with moderately severe atopic dermatitis that does not respond adequately to corticosteroids, researchers reported during a poster session here on June 30th at the World Allergy Congress (WAC).

        Tacrolimus ointment is currently recommended as a second-line therapy for moderately severe to severe atopic dermatitis in patients older than 2 years. However, most studies of its efficacy compared it only to vehicle ointment. Very little information exists on its efficacy compared to corticosteroids.

        Therefore, Peter D. Arkwright, MD, Senior Lecturer in Paediatric Immunology, University of Manchester, Manchester, United Kingdom, and colleagues conducted a head-to-head comparison between tacrolimus and corticosteroids for treatment of children with atopic dermatitis.

        The study enrolled 41 male and 36 female paediatric patients with moderately severe to severe atopic dermatitis enrolled. Ages ranged from 6 months to 18 years; median age was 5 years.

        Researchers evaluated the effectiveness of 0.03% tacrolimus ointment compared to the standard topical corticosteroid treatment. If the 0.03% tacrolimus preparation had no effect, the 0.1% strength was used. The stronger product is not approved for paediatric use in the United States or the U.K., but about 25% of children with moderately severe to severe atopic dermatitis respond to it, Dr. Arkwright said.

        Of 74 children who completed the study, 81% experienced greater improvement with the ointment compared to topical corticosteroids, Dr. Arkwright said. Of those who responded to tacrolimus, about two-thirds responded to the 0.03% preparation, while the remainder required the 0.1% ointment.

        "Tacrolimus seems to have a niche in the management of these patients, but it's not a panacea; about 20% of these children will not respond," Dr. Arkwright said.

        Children receiving moderate or potent topical corticosteroids prior to entering the study had a significantly lower chance of responding to tacrolimus, which suggests that children whose eczema was inadequately controlled by the corticosteroids were less likely to respond to tacrolimus ointment in either strength, he added.

        Six children complained of burning and redness for 3 to 5 days after application of tacrolimus, but all of those cases resolved within a week, and there were no other severe adverse effects.

        Dr. Arkwright estimated that about 2% to 5% of children with eczema have the more severe forms that might benefit from tacrolimus.


        [Presentation title: Blinded Side-to-Side Comparison of Topical Corticosteroid and Tacrolimus Treatment in Children With Moderate-Severe Eczema. Poster 1156]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send